Two Sigma Advisers
LYEL icon

Two Sigma Advisers’s Lyell Immunopharma LYEL Stock Holding History

Two Sigma Advisers’s Portfolio LYEL Stock Details LYEL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-19,560
Closed -$210K – 2440
2025
Q1 		$210K Buy
19,560
+4,240
+28% +$51.9K ﹤0.01% 2118
2024
Q4 		$196K Buy
15,320
+9,035
+144% +$179K ﹤0.01% 2130
2024
Q3 		$173K Sell
6,285
-880
-12% -$25.9K ﹤0.01% 2104
2024
Q2 		$208K Buy
7,165
+1,810
+34% +$86.2K ﹤0.01% 2201
2024
Q1 		$239K Buy
5,355
+4,585
+595% +$196K ﹤0.01% 2153
2023
Q4 		$29.9K Buy
+770
New +$27.7K ﹤0.01% 2431
2023
Q2 		– Sell
-3,680
Closed -$174K – 2548
2023
Q1 		$174K Buy
3,680
+3,150
+594% +$168K ﹤0.01% 2292
2022
Q4 		$36.8K Buy
+530
New +$52.6K ﹤0.01% 2386

Other funds holding LYEL

AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
MM
MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return
FCMI
Foresite Capital Management IV Larkspur, California $290M AUM 143.88% 1-Year Est. Return
OPL
Orland Properties Ltd Road Town, Tortola, British Virgin Islands $202M AUM 2.79% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
VP
venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FCMV
Foresite Capital Management V Larkspur, California $362M AUM 386.37% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Two Sigma Advisers's LYEL Position: Q2 2025 in Review

Two Sigma Advisers sold out of Lyell Immunopharma (LYEL) in Q2 2025, closing a stake of 19,560 shares — an estimated $210K sold.

Two Sigma Advisers first reported a position in LYEL in Q4 2022 and held it in 8 quarters. The position peaked at $239K in Q1 2024. 69 funds tracked by Wall St. Rank hold LYEL as of Q2 2025.

  • Two Sigma Advisers reported no remaining Lyell Immunopharma position as of Q2 2025 after selling out during the quarter.
  • Two Sigma Advisers sold 19,560 Lyell Immunopharma shares in Q2 2025, an estimated $210K.
  • Two Sigma Advisers first reported a position in Lyell Immunopharma in Q4 2022 and held it in 8 quarters.
  • Two Sigma Advisers's Lyell Immunopharma position peaked at $239K in Q1 2024.
  • 69 funds tracked by Wall St. Rank held Lyell Immunopharma as of Q2 2025.

Based on Two Sigma Advisers's 13F filing for Q2 2025, filed 14 Aug 2025.